Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair, and in post-traumatic stress disorder (PTSD). Identified neuroplastogen candidates with potential to promote brain-derived neurotrophic factor (BDNF) signaling, a therapeutic target for neurodegenerative disease. Announced the withdrawal of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric's U.S. Patent No. 12,138,276, relevant to the bretisilocin (GM-2505) molecule acquired by AbbVie, Inc. Continued to strengthen its expansive IP portfolio, receiving multiple patents and notices of allowance for its EVM301 Series and EVM401 Series. Received FDA response allowing for streamlined plans for EB-003 IND submission and successfully completed pre-IND dose range finding studies. Achieved key manufacturing milestones in the chemistry, manufacturing, and controls (CMC) development of EB-003. Net loss attributable to stockholders was $4.0 million for the fourth quarter ended December 31, 2025, including $0.3 million in net non-cash expense, with a basic and diluted loss per share of $6.12. Cash-on-hand was $4.7 million for the quarter ended December 31, 2025. Raised a total of $4.9 million during the fourth quarter of 2025 from a warrant inducement and an at-the-market offering. Total gross proceeds raised during fiscal year 2025 was $12.2 million. Completed a reverse stock split of its common stock on October 28, 2025, at a ratio of 1 post-split share for every 12 pre-split shares. Subsequent to year-end, raised approximately $1.5 million in January 2026 and $1.45 million in February 2026 through offerings. Relocated corporate headquarters to Cambridge, MA, to leverage the Greater Boston biotech ecosystem. Executed two licensing agreements with Restoration Biologics LLC and expanded collaboration with TOTEC Pharma LLC.